Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), an Ireland-based pharmaceutical company, filed this Current Report on August 5, 2020. The filing announces the release of earnings results for the second quarter ended June 27, 2020. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in this text.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for non-GAAP financial measures used in the full report.
Material Changes and Adjustments
The Company outlines specific adjustments made to derive non-GAAP measures for the three and six months ended June 27, 2020, compared to the prior year periods. These adjustments include:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Restructuring charges and other termination benefits.
- Unusual litigation costs.
- Foreign currency translation movements.
- Net sales from specific acquisitions (Ranir and Dr. Fresh) and divestitures (Animal health and Canoderm).
- Impairment charges and separation expenses (noted in prior year comparisons).
Guidance, Outlook, and Management Commentary
Management utilizes non-GAAP measures to evaluate ongoing operating trends, facilitate comparability between periods, and assess future prospects. These measures exclude items that obscure underlying business trends, such as impairment charges and acquisition-related costs. The Company emphasizes that adjusted gross margin and operating margin allow for better comparison with peer businesses. No specific forward-looking guidance or numerical outlook is provided in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual GAAP and non-GAAP revenue, net income, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the impact of excluded items like amortization and restructuring.
- Assess the impact of foreign currency translation on reported growth rates.
- Confirm the treatment of the Ranir and Dr. Fresh acquisitions in organic growth calculations.
- Check for any updates on unusual litigation or contingent consideration adjustments mentioned in the adjustments list.